·
1 Min Read

AMA statement on FDA authorization of first COVID-19 vaccine

Today's decision a monumental milestone.

Press Releases
·
2 Min Read

AMA statement on COVID-19 vaccine allocation recommendations

We strongly support ACIP’s evidence-based interim recommendation adopted today for phase 1a of the COVID-19 vaccine allocation process.

Press Releases
·
3 Min Read

AMA, AHA, ANA back science-based COVID-19 vaccine process, urge vigilance

Leading U.S. medical, nursing, health organizations affirmed their commitment to ensuring COVID-19 vaccines are evaluated through a rigorous scientific process.

Press Releases
Variety of health care professionals with vials and microscope
·
5 Min Read

Essential terms doctors need to know about COVID-19 vaccines

People want a safe and effective SARS-CoV-2 vaccine. These terms are ones your patients will be asking about. Learn more with the AMA.

Infectious Diseases
Anthony S. Fauci, MD
·
5 Min Read

Dr. Fauci: Why FDA’s coronavirus vaccine review will be politics-free

Anthony S. Fauci, MD, details the layers of independent analysis involved in the review and approval of any vaccine to protect against SARS-CoV-2.

Infectious Diseases
Lab testing
·
3 Min Read

FDA’s SARS-CoV-2 vaccine review needs major dose of transparency

With vaccine hesitancy at an all-time high, the FDA must provide “utmost level of transparency” on how they’ll vet vaccine candidates for safety, efficacy.

Infectious Diseases
Microscope
·
5 Min Read

How evidence is guiding COVID-19 vaccine development

AMA President Susan R. Bailey, MD, explains the mechanisms in place to ensure a safe and effective immunization against the deadly respiratory illness.

Infectious Diseases
·
4 Min Read

Top news stories from AMA Morning Rounds®: Week of July 27, 2020

In the news: Young adults with COVID-19 may take weeks to recover, review finds U.S. vaccines are safe and more.

Publications & Newsletters
Syringe
·
3 Min Read

Top ethicist makes the case for COVID-19 vaccine challenge trials

Arthur Caplan, PhD, says the enormous toll of COVID-19 justifies a different approach to vaccine development. He examines how to proceed with human challenge trials for a COVID-19 vaccine.

Infectious Diseases